Advertisement

AstraZeneca, Oxford Uni buoyed by vaccine response

British pharma giant AstraZeneca said on Monday trials of its coronavirus vaccine pioneered with Oxford University had shown "encouraging" responses among the elderly, as well as younger participants.

AstraZeneca, Oxford Uni buoyed by vaccine response
In this file photo taken on September 11, 2020 Laboratory technicians handle capped vials as part of filling and packaging tests for the large-scale production and supply of the University of Oxford’s COVID-19 vaccine candidate, AZD1222, conducted on a high-performance aseptic vial filling line at the Italian biologics’ manufacturing facility of multinational corporation Catalent in Anagni, southeast of Rome. The clinical trial for the Covid-19 vaccine being developed by AstraZeneca and Britain's University of Oxford has resumed in the United States, the drugmaker said October 23. "The Food and Drug Administration (FDA) today authorised the restart in the US, following the resumption of trials in other countries in recent weeks," AstraZeneca said in a statement. AFP
The potential vaccine, one of 10 around the world in the most advanced phase III of trials, showed "strong immune responses" in all adult groups during the previous stage, according to an update from Oxford.

An AstraZeneca spokesman said the initial results "further build the body of evidence for the safety and immunogenicity" of its experimental vaccine.

"It is encouraging to see immunogenicity responses were similar between older and younger adults, the spokesman added.

The positive news emerged in data on the safety and immune responses of participants in the phase II stage of the trial Oxford has submitted for peer review in a medical journal.  

They include results for UK volunteers aged 56-69 and over 70, with formal publication of the data expected "in the coming weeks".

"Our ongoing trials will provide further data, but this marks a key milestone and reassures us that the vaccine is safe for use and induces strong immune responses in both parts of the immune system in all adult groups," the university said.

Oxford and AstraZeneca have been trialing their potential vaccine for months in various countries around the world. 

It was suspended worldwide on September 6 after a participant's illness but resumed shortly thereafter in Britain, and in the following weeks in South Africa, Brazil, and Japan.

Authorities determined the illness was not apparently linked to the vaccine, with the US Food and Drug Administration also authorising the restart in the United States at the weekend. 

The AstraZeneca/Oxford vaccine is one of the most promising and advanced in the world to combat the global pandemic, which has now claimed the lives of 1.1 million people.

Many countries are counting on using it to inoculate their populations. 

The drugmaker pre-sold hundreds of millions of doses on several continents and signed partnership deals with other producers to ensure the doses could be made locally.

UK Health Secretary Matt Hancock further fuelled optimism Monday, noting in an interview that once approved the "bulk" of the vaccine's rollout could occur in Britain before next summer.

Topics: AstraZeneca , Oxford University , potential vaccine , Matt Hancock
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by manilastandard.net readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of manilastandard.net. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.
AdvertisementGMA-Working Pillars of the House
Advertisement